India, Feb. 4 -- Zydus Lifesciences has secured approval from the U.S. Food and Drug Administration to market a generic diabetes medication in the United States.
The company received tentative approval for Dapagliflozin tablets in 5 mg and 10 mg strengths, according to a regulatory filing.
Dapagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class and is prescribed alongside diet and exercise to help improve blood sugar control in adults with type 2 diabetes. The approval is expected to strengthen Zydus' presence in the US generics market and expand its diabetes care portfolio.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....